Keywords
How to Cite
Abstract
The effective approach to the interaction between type 2 diabetes and cardiovascular diseases emerges as a complex challenge in clinical practice, requiring an integrative approach that considers various facets of prevention and treatment. Current intervention strategies for patients facing this conjunction of conditions emphasize the importance of a holistic view, incorporating both pharmacological and non-pharmacological approaches to provide comprehensive and personalized care. A critical literature review explores pharmacological interventions such as hypoglycemics, antihypertensives, and statins, while also examining non-pharmacological therapies such as lifestyle changes, dietary modifications, and exercise programs.
The detailed analysis of these therapeutic modalities underscores the demand for a personalized approach in managing the interaction between type 2 diabetes and cardiovascular diseases, recognizing the diversity in individual responses to different interventions. Additionally, the growing role of multidisciplinary interventions is highlighted, fostering collaboration among various healthcare professionals, including endocrinologists, cardiologists, nutritionists, and health educators. This synergy aims to offer patients a variety of therapeutic options, taking into account the unique complexities associated with this clinically complex condition.
Finally, this research emphasizes future implications and promising areas of study in managing the interaction between type 2 diabetes and cardiovascular diseases. This includes the development of innovative therapeutic approaches, advances in regenerative medicine, and a deeper understanding of the pathophysiological foundations of these interrelated conditions. By providing a comprehensive view of current and future strategies, this article seeks to genuinely contribute to improving the quality of life for patients facing challenges arising from the complex interaction between type 2 diabetes and cardiovascular diseases.
References
Aroda, V. R., & Eckel, R. H. (2022). Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. Diabetes Obes Metab, 24(2297–2308).
Bellavite, P., Fazio, S., & Affuso, F. (2023). A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention. Molecules, 28, 4491.
Brandt-Jacobsen, N. H., et al. (2023). Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial. BMC Cardiovascular Disorders, 23(1), 175.
Gant, C. M., et al. (2023). Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real-life population of complicated type 2 diabetes – contraindications and opportunities. BMC Nephrology, 24(1), 240.
Hinnen, D., et al. (2023). Type 2 diabetes and cardiovascular disease: risk reduction and early intervention. Nature Reviews Cardiology, 20, 685-695.
Lo, S.-C., et al. (2023). Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database. Diabetes Research and Clinical Practice, 200, 110685.
Morieri, M. L., et al. (2023). Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care. Diabetes Ther, 14, 2159–2172.
Østergaard, H. B., et al. (2023). Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study. Diabetes Obes Metab, 25, 435-443.
Otto, T., et al. (2023). Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes Research and Clinical Practice, 200, 110685.
Salem, A. M., et al. (2023). Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. International Journal of Cardiology, 377, 104-111.
Wi, M., et al. (2023). Systematic Review Effectiveness and Safety of Fufang Danshen Dripping Pill (Cardiotonic Pill) on Blood Viscosity and Hemorheological Factors for Cardiovascular Event Prevention in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. Medicina, 59, 1730.
Wong, N. D., & Sattar, N. (2023). Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nature Reviews Cardiology, 20, 685-695.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Marianna Oliveira Cunha Fontes , André Tomé de Sousa , Antônio Célio de Oliveira Junior, Brenda Achtschin Fernandes, Luana Bretas dos Santos Leonha